Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
injection, CagriSema, to reduce excess body weight and maintain weight reduction in the long term in adults with obesity or overweight. The FDA is expected to review the application in 2026. The candidate is intended to be used in conjunction with a reduced-calorie diet and increased physical activity in patients who have at least one weight-related comorbid condition. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Novo Nordisk's blockbuster obesity drug, Wegovy (semaglutide 2.4 mg). The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness and helping individuals consume fewer calories. If approved, NVO's CagriSema would be the first injectable therapy to combine a GLP-1 RA with an amylin analogue. Novo Nordisk's NDA is based on statistically significant results from two late-stage studies, the 68-week phase III REDEFINE 1 study of CagriSema in obesity patients without diabetes and the 68-week ph
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs [Yahoo! Finance]Yahoo! Finance
- This is how exposed European Big Pharma is to the U.S. [MSNBC.com]MSNBC.com
- UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress [Yahoo! Finance]Yahoo! Finance
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
- Obesity pill race heats up [CNBC]CNBC
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website